Peptide Decoding
Two peptide vials side by side on a dark surface
Step 02 / Compare

Compare peptides side by side

Type two or more compounds the way you'd type them into Google. Spelling doesn't have to be right.

4/4

Separate them with vs, a comma, or +. Up to 4 compounds.

Try

These 4 work in 3 different ways, so they are not straight substitutes for each other.

/compare/bpc-157-vs-tb-500-thymosin-beta-4-vs-coremend-blend-vs-kpv
ComparisonBPC-157
Body Protection Compound 157 · Pentadecapeptide BPC 157
TB-500 / Thymosin Beta-4
TB4 · thymosin beta 4
Coremend blend (TB-500 / BPC-157 / KPV)
Coremend · TB-500 + BPC-157 + KPV
KPV
lysine-proline-valine
How it works
How it works

BPC-157 is a 15-amino-acid chain based on a protective protein found in stomach acid. It is one of the most widely used peptides here and one of the least studied in humans.

How it works

TB-500 is a fragment of thymosin beta-4, a protein your body already uses when tissue needs repairing. Its main job is helping cells move.

How it works

Coremend sits between two blends this library already covers, and the interesting part is the ratio rather than the ingredients.

How it works

KPV is three amino acids long: the tail end of alpha-MSH with the part that causes tanning removed. It keeps the anti-inflammatory action and loses the pigmentation.

What it is
A popular healing peptide for injuries, gut, and joint or tendon pain.
A recovery peptide for healing muscle and tendon, often paired with BPC-157.
A named healing triple that is the Wolverine blend with KPV added.
A tiny anti-inflammatory peptide for gut and skin, with no tanning effect.
Status
Research only
Research only
Research only
Research only
Typical dose
0.25–0.5 mg per dose
2–2.5 mg per dose
0.25–0.5 mg per day
0.2–0.5 mg per day
How often
1-2x daily
Twice a week
Varies
Daily, 4-8 wk courses
Stays active
About 8 to 30 minutes in rats
Not established
None of the three has a published human figure
Nothing published
Dose comes from
Community practice
Community practice
Community practice
Community practice
Cycled?
Commonly run in 4 to 8 week blocks around an injury, then stopped Community practice
Commonly a loading period of 4 to 6 weeks, then less often, then stopped Community practice
Not established for the blend No established range
Taken in daily, 4-8 wk courses Community practice
What it does
Drug class
Repair peptide
Repair peptide
TB-500 + BPC-157 + KPV blend
Anti-inflammatory tripeptide
Used for
A popular healing peptide people use to bounce back faster from injuries, gut problems, and joint or tendon pain. It is a favorite for recovery.
A recovery peptide used to heal muscles, tendons, and other injuries faster and move more freely. It is often paired with BPC-157.
An injected three-peptide blend sold for tissue repair, recovery and inflammation.
A tiny anti-inflammatory peptide people use to calm inflammation in the gut and skin, popular for IBD, colitis, and skin flare-ups.
Receptors hit
—
—
—
—
Numbers
Full dose line
0.25 up to 0.5 mg per dose (start low, increase slowly)
2 up to 2.5 mg per injection (start low, increase slowly)
0.25 up to 0.5 mg BPC-157 per day (the rest follows your ratio)
0.2 up to 0.5 mg per day (start low, increase slowly)
Why that cycle
The block length is a community convention tied to how long a soft-tissue injury takes to settle. No human study has tested a duration, and none has looked at what long-term use does, so there is no evidence either that a break is needed or that it is safe to skip one.
The loading-then-maintenance shape comes from community practice. No human study has tested a duration or a break.
No schedule has been studied for this combination. The components have different clearance times and different conventional frequencies, so a single shared schedule is a convenience of the vial rather than a finding.
Course dosing is how this one is normally used. Where the course length comes from is the thing to check: for most compounds in this pattern it is convention rather than a tested schedule.
Weight / effect
Not measured in a trial
Not measured in a trial
Not measured in a trial
Not measured in a trial
Chain length
15 residues
43 residues
Not disclosed
3 residues
Common vial
5 mg
10 mg
—
10 mg
Before you start
Route
Under the skin, into muscle, or by mouth
Under the skin or into muscle
Under the skin (subcutaneous)
By mouth, under the skin, or on the skin
Do not use if
Active cancer, as a precaution given that it promotes new blood-vessel growth
Pregnancy
Banned in drug-tested sport
Active cancer, as a precaution given the tissue-growth mechanism
Pregnancy
Banned in drug-tested sport
Pregnancy or breastfeeding
Active cancer, as a precaution with anything that promotes tissue or blood-vessel growth
Anyone competing in drug-tested sport, because TB-500 is named on the WADA prohibited list
Anyone who wants established safety data, because none exists for this combination in humans
No controlled human trials exist, so no contraindications are established
Pregnancy

What separates them

Proof behind the dose. Every dose here comes from community practice. Not one is backed by a published human study, which is worth knowing before you read the numbers as if they were equivalent.

How you take it. BPC-157 is sold by mouth and injected; KPV is sold on the skin, by mouth and injected. TB-500 and Coremend blend are injected.

What doesn't differ: None of them has a measured effect size from a published trial, so there is no number to rank them on.

Difference map
Each column keeps its compound color below. A shared gray row means the same answer; colored cells show where they split.
BPC-157
TB-500 / Thymosin Beta-4
Coremend blend (TB-500 / BPC-157 / KPV)
KPV
PROOF
Community practice
Community practice
Community practice
Community practice
ROUTE
By mouth and injected
Injectable
Injectable
On the skin, by mouth and injected

What people actually report

BPC-157

  • Almost all the evidence so far is from animal studies, not people.
  • There is a theoretical cancer concern because it promotes new blood-vessel growth.
  • Banned in drug-tested sport.
Stop and get help if
  • Signs of an allergic reaction
  • New lumps or masses

TB-500 / Thymosin Beta-4

  • It is mostly tested in animals, with limited human data.
  • Most products sold are a fragment rather than the full protein.
  • Banned in drug-tested sport.
Stop and get help if
  • Signs of an allergic reaction
  • New lumps or masses

Coremend blend (TB-500 / BPC-157 / KPV)

  • No trial has tested this combination in people.
  • The uneven ratio pushes TB-500 above its usual weekly amount if the blend is dosed daily.
Stop and get help if
  • Signs of an allergic reaction, including spreading hives, facial or throat swelling, or trouble breathing
  • Redness, heat, or pus at the injection site, which can signal infection

KPV

  • There are no human trials yet, so safety is inferred from animal work.
  • Unlike some similar peptides, it does not cause tanning.
Stop and get help if
  • Signs of an allergic reaction
  • Anything unusual, given the absence of human data

Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.

People also compare

This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.

Commonly confused peptides

Long-form breakdowns of the pairs people confuse most, traced to primary sources.

Metabolic and weight loss

Semaglutide vs Tirzepatide vs Retatrutide

One head-to-head trial, three pivotal trials, and why their headline weight-loss figures are not directly comparable.

Read comparison ›
Skin and repair

GHK vs GHK-Cu

The same sequence, with or without copper: topical trial evidence, formulation caveats and the research-vial market.

Read comparison ›
Metabolic and weight loss

Semaglutide vs Liraglutide

In STEP 8, semaglutide produced more weight loss than liraglutide; liraglutide offers generic availability and daily dosing.

Read comparison ›
Muscle

Follistatin vs ACE-031

ACE-031 built muscle but was stopped for vascular side effects. Follistatin protein has not been tested by injection in people.

Read comparison ›
Metabolic and weight loss

Liraglutide vs Semaglutide vs Tirzepatide vs Retatrutide

One receptor, then two, then three, and the numbers climb with them. Only two of the three steps have a head to head behind them.

Read comparison ›
Growth hormone

HGH vs Sermorelin

Distributing HGH for anti-aging is a federal felony carrying five years. Sermorelin lost to it commercially in 2008 and can still be legally compounded.

Read comparison ›
Muscle

IGF-1 LR3 vs IGF-1 DES

Neither has a single published human trial, and sources give LR3's half-life as anywhere from 6 to 30 hours. There is an FDA approved IGF-1, and it is neither of these.

Read comparison ›
Healing and recovery

Thymosin Alpha-1 vs LL-37

One is approved in 35 countries and its largest trial found nothing. The other has never been injected in a published study.

Read comparison ›
Metabolic and weight loss

Cagrilintide vs Semaglutide

Both were tested in the same trial, in the same people, over the same 68 weeks. Semaglutide won on weight, and the combination beat both while coming in below their sum.

Read comparison ›
Metabolic and weight loss

Petrelintide vs Semaglutide

Semaglutide produced 16.9 percent in STEP 1 against petrelintide's 10.7 in ZUPREME-1. Petrelintide's case is tolerability: no vomiting at its best dose, and no added dropouts over placebo.

Read comparison ›
Metabolic and weight loss

Semaglutide vs Tirzepatide

Tirzepatide won the head-to-head at 20.2 percent against 13.7. The 47 percent figure everyone quotes is relative; the absolute gap is 6.5 points, from an open-label trial.

Read comparison ›
Metabolic and weight loss

Retatrutide vs Tirzepatide

Retatrutide's 28.3 percent is being set against tirzepatide's 22.5 percent. Different trials, different lengths, and no trial yet comparing the two directly.

Read comparison ›
Sexual and hormonal

PT-141 vs Kisspeptin

Both are sold for sex. One works on desire and is FDA approved, the other works on hormones and stops working within two weeks.

Read comparison ›
Longevity

MOTS-c vs SS-31

One has an FDA approval and a failed Phase 3. The other has never been given to a person in a published study.

Read comparison ›
Growth hormone

Tesamorelin vs CJC-1295

Two GHRH analogs tested for the same condition. One completed two Phase 3 trials and got approved. The other's Phase 2 was halted in 2006 and never restarted.

Read comparison ›
Growth hormone

Tesamorelin vs HGH

Both are FDA approved. Tesamorelin asks your pituitary for growth hormone and HGH is the hormone itself, and only one is a felony to distribute off-label.

Read comparison ›
Skin and repair

Melanotan I vs Melanotan II

Not two versions of one compound. One is an FDA approved implant for a rare disease, the other is approved nowhere and warned against by four regulators.

Read comparison ›
Longevity

Epitalon vs MOTS-c

Two longevity peptides with no published human trial between them. Epitalon's famous human data belongs to a bovine extract, and MOTS-c is something your body already makes.

Read comparison ›
Longevity

Glutathione vs NAD+

Both are sold as injections. NAD+ cannot enter cells intact, and a six month trial found oral glutathione raising body stores the injection is meant to fix.

Read comparison ›
Cognitive and mood

Noopept vs Semax

Two Russian medicines no Western regulator has assessed. Semax is a seven amino acid peptide; Noopept is not a peptide at all.

Read comparison ›
Cognitive and mood

Semax vs Selank

Same Russian lab, same seven amino acids, built for different problems: Semax for alertness, Selank for anxiety.

Read comparison ›
Skin and repair

GHK-Cu vs Matrixyl

Two topical skin peptides with very different evidence: one carries copper, one carries a fat tail, and Matrixyl 3000, a widely used formulation, is built on the same tripeptide as GHK-Cu.

Read comparison ›
Healing and recovery

BPC-157 vs TB-500

Both are sold for tendon and muscle repair. BPC-157's human trials were enemas for ulcerative colitis, and TB-500's trials did not even use TB-500.

Read comparison ›
Healing and recovery

BPC-157 vs KPV

BPC-157's Phase 2 results were never published. KPV has no human trial; neither was tested as an injection for the uses it is sold for.

Read comparison ›
Growth hormone

CJC-1295 with DAC vs without DAC

One name, two drugs: one has a measured half-life and three published human trials, the other has never been tested in a person.

Read comparison ›
Growth hormone

Ipamorelin vs CJC-1295

They act on different receptors and are usually sold in the same vial. Each has human trials; the combination everyone buys has none.

Read comparison ›
Growth hormone

MK-677 vs Ipamorelin

Same receptor, a pill against an injection. MK-677 has far more human data, and that is exactly why we know more about what is wrong with it.

Read comparison ›
Healing and recovery

KLOW vs GLOW

These are not two products. One contains the other: KLOW is GLOW plus KPV, and neither blend has ever been tested as a blend.

Read comparison ›
Growth hormone

Sermorelin vs Ipamorelin

Two growth hormone peptides sold side by side. One was an approved drug and can still be compounded on prescription. The other was voted down in October 2024.

Read comparison ›
Sexual and hormonal

Enclomiphene vs HCG vs Gonadorelin vs Kisspeptin

Three sit on one hormone chain and the fourth skips it. The one with the best trial evidence was rejected by the FDA in 2015 and abandoned.

Read comparison ›
Healing and recovery

Thymosin Alpha-1 vs Thymosin Beta-4 vs TB-500

Two are unrelated proteins sharing a name by accident. The third is seven amino acids taken from the second, and no trial has injected any of them.

Read comparison ›
Longevity

NAD+ vs NMN vs NR

Three points on one pathway: compare cellular uptake, human evidence and changing supplement rules.

Read comparison ›
Growth hormone

Sermorelin vs Tesamorelin vs Ipamorelin vs CJC-1295

Three act on the GHRH receptor and one copies ghrelin. Only tesamorelin is approved, and the two with the weakest outcome data were both voted down by the FDA in late 2024.

Read comparison ›
Metabolic and weight loss

GLP-1 agonists compared

Twenty compounds act on the GLP-1 receptor. Eight are FDA approved. Most trial doses are not the same thing as a label dose. Here is what separates them.

Read comparison ›
Metabolic and weight loss

CT-388 vs Zovaglutide

Weekly dual-receptor CT-388 and monthly GLP-1 zovaglutide have not been compared head to head; their trial results use different measures and follow-up periods.

Read comparison ›
Muscle

ACE-031 vs GDF-8

Not two alternatives: ACE-031 is a drug built to neutralise GDF-8, the protein better known as myostatin. One has human trial data; the other is the brake itself.

Read comparison ›

36 published

Compare is one of the free tools on the site. See all tools.